2021 Revenues ($USD) : $362,048,000
2021 R&D spend : $45,600,000
2021 Number of Employees : 843
Fiscal Year End : 12/31/2020
Key People : Keith Grossman, chair, CEO and president; Rod MacLeod, CFO; David Caraway, chief medical officer; Kashif Rashid, general counsel; Niamh Pellegrini, chief commercial officer; Lori Ciano, chief human resources officer; Michael Carter, VP, global sales; Richard Carter, VP, finance, corporate controller; Christofer Christoforou, VP, technical operations; Julie Dewey, VP, investor relations and corporate communications; Donald Middlebrook, VP, clinical regulatory and quality; Claire Smith, VP, customer excellence; Jon Shear, VP, corporate development.

About the company: Nevro aims to disrupt the space of traditional spinal cord stimulation (SCS) that has been around for more than 30 years. Founded in 2006, the Redwood City, California–based company introduced its next-generation approach for treating patients with chronic pain — 10kHz therapy — which it designed to offer patients significant pain relief and no paresthesia. Nevro’s Senza SCS system for 10 kHz therapy received the CE mark in 2010 and FDA approval in 2015. Today, the company’s SCS systems hold approval in the U.S. to deliver all available SCS frequencies and the most waveform types in a single product as it seeks to help patients achieve long-term pain relief. –SW